2025年度业绩预告 证券代码：301103 证券简称：何氏眼科 公告编号：2026-003 辽宁何氏眼科医院集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 1.持续优化业务结构，高毛利业务驱动增长：公司推进业务结构优化，加大 对高毛利的屈光业务与视光业务的投入和发展所致。 2.成本与费用管控成效显著：公司全面推行精细化运营管理，通过集中采购 优化、供应链效率提升、数字化运营等赋能，实现降本增效，从而带动了整体盈 利能力的提升。 3.推进低效资产出清：公司对部分长期效益不佳或战略协同性较弱的业务单 元实施了主动整合、调整或剥离，进一步优化了资产配置效率。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 2、预计的业绩：□亏损 √扭亏为盈 □同向上升 □同向下降 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股东的 | 盈利：2,400万元–3,600万元 | 亏损：2,739.82万元 | | 净利润 | | | | 扣除非经常性损 ...

董秘： 尊敬的投资者您好，公司始终坚持以创新科技驱动发展，根据公司战略规划，坚守"科技人 文"理念，深化"智慧光明城"战略，推动数字化、精准医疗等前沿技术与眼科医疗深度融合，构建全生 命周期眼健康管理体系。公司当前持有相应额度的货币资金，主要是为了应对外部环境、医疗行业政策 以及消费趋势变化可能带来的挑战，确保公司具备稳健的抗风险能力和持续经营能力。与此同时，公司 将资金的使用聚焦于两个方向：一是在眼科及眼视光领域的机构运营场景中，可实现降本增效、提升患 者及客户体验的智慧医疗工具的应用；二是围绕优化眼健康服务，布局上下游配套产品及未来前瞻性技 术，持续完善眼健康服务生态。公司将更聚焦于智慧医疗技术的应用落地，而非技术研发本身。公司将 积极寻找并整合成熟的计算机视觉、语言模型等技术，以此优化患者就医流程、提升客户服务体验；同 时，也会密切关注并探索逐步成熟的智能技术在运营管理等环节的应用，助力降本增效。公司始终坚持 以眼科主业为核心，谨慎评估相关技术融合的可行性，后续如有重大业务进展或达到信息披露标准的事 项，公司将严格按照相关规定履行信息披露义务。敬请投资者注意投资风险，感谢您的关注与支持！ 截至2026年 ...

Core Viewpoint - He Eye Hospital has confirmed that recent shareholder reduction actions were conducted in compliance with legal regulations and are based on the shareholders' own financial needs, emphasizing respect for shareholders' rights and market choices [1] Group 1: Shareholder Actions - The company stated that shareholders have fulfilled their information disclosure obligations regarding the reduction of shares [1] - The reduction actions are driven by the shareholders' independent financial decisions [1] Group 2: Company Strategy - He Eye Hospital will continue to focus on long-term value creation while enhancing internal operational efficiency and core service capabilities [1] - The company aims to adapt to global technological innovations and economic development trends by exploring and promoting sustainable public health service models in the ophthalmology sector [1] - The commitment to social responsibility and corporate value is highlighted, with a focus on safeguarding the long-term interests of all shareholders [1]

Group 1 - The core viewpoint of the news is that He Eye Hospital has shown a slight increase in stock price and has low financing and margin trading balances, indicating a cautious market sentiment towards the company [1] Group 2 - As of January 22, He Eye Hospital's stock price increased by 0.47%, with a trading volume of 42.887 million yuan [1] - The financing buy-in amount on January 22 was 2.5777 million yuan, while the financing repayment was 2.1286 million yuan, resulting in a net financing buy-in of 0.4490 million yuan [1] - The total financing and margin trading balance for He Eye Hospital as of January 22 was 64.8946 million yuan, which is 1.91% of its circulating market value and below the 50th percentile level over the past year [1] Group 3 - As of September 30, the number of shareholders for He Eye Hospital was 9,888, a decrease of 8.55% from the previous period [2] - The average circulating shares per person increased by 60.07% to 12,301 shares [2] - For the period from January to September 2025, He Eye Hospital achieved an operating income of 855 million yuan, a year-on-year decrease of 1.11%, while the net profit attributable to the parent company was 54.3953 million yuan, a year-on-year increase of 232.18% [2] Group 4 - He Eye Hospital has distributed a total of 348 million yuan in dividends since its A-share listing, with 275 million yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders included Rongtong Health Industry Flexible Allocation Mixed A/B (000727), holding 2.7015 million shares, a decrease of 93,200 shares from the previous period [3]

Core Viewpoint - He Eye Hospital, a leading ophthalmology institution in Northeast China, is facing challenges including a significant reduction in shareholder value and management changes, alongside underperformance in multiple investment projects since its IPO in 2022 [1][2][4]. Group 1: Company Performance and Financials - He Eye Hospital's revenue is heavily concentrated in Liaoning Province, accounting for 94.31% of total revenue in 2024 [2]. - The company reported a net profit of 32.59 million yuan in 2022, a significant decline of 62.26% year-on-year, despite distributing dividends of 158 million yuan, which exceeded its net profit [2]. - For 2024, the company is projected to achieve a revenue of 1.096 billion yuan, reflecting a year-on-year decrease of 7.56%, with a net loss of 27.40 million yuan [3]. Group 2: Investment Projects and Challenges - Several investment projects initiated post-IPO have not met expected returns, with significant losses reported in projects such as the Beijing and Chongqing hospitals, which recorded losses of 90.85 million yuan and 69.51 million yuan respectively [4][5]. - The company has faced delays in project timelines, with the expected operational status for some projects pushed back to December 2026 and March 2027 [4][6]. Group 3: Management Changes and Shareholder Actions - In December 2025, the company underwent significant management changes, including the resignation of the general manager and the secretary of the board, which may impact operational stability [7][8]. - The fourth largest shareholder, Advanced Manufacturing Industry Investment Fund, has announced plans to reduce its stake by up to 310,610 shares, representing 1.97% of the total share capital, following a previous reduction in 2025 [8][9].

Group 1 - The core point of the article is the announcement of a share reduction plan by the fourth largest shareholder, Advanced Manufacturing Fund, for He Shi Eye Hospital, which is set to take place from February 7, 2026, to May 6, 2026, involving a maximum reduction of 3.1061 million shares, accounting for 1.97% of the total share capital [1] - There has been a significant management change at He Shi Eye Hospital, with the chairman's son taking over as general manager and the company secretary resigning in December 2025 [1] - Since its listing in 2022, several fundraising projects of He Shi Eye Hospital have not met expected returns or progress targets [1] Group 2 - As of January 20, 2026, He Shi Eye Hospital's closing price was 21.51 yuan, giving it a market capitalization of approximately 3.399 billion yuan [1] - If the Advanced Manufacturing Fund reduces its holdings at the price of 21.51 yuan, it would realize over 66 million yuan in cash [1]

Core Viewpoint - He Eye Hospital, a leading ophthalmology institution in Northeast China, is facing challenges due to management changes, underperformance of fundraising projects, and a significant decline in profits since its IPO in 2022 [1][2][3]. Group 1: Management Changes - In December 2025, the company experienced significant management changes, including the resignation of the general manager and the secretary of the board [8][9]. - The new general manager, He Xingru, is the son of the actual controllers, He Wei and He Xiangdong, indicating a continuation of family control [8][9]. Group 2: Financial Performance - He Eye Hospital's revenue for 2024 is projected to be 1.096 billion yuan, a decrease of 7.56% year-on-year, with a net loss of 27.3982 million yuan, a decline of 143.11% [2]. - The company reported a net profit of 54.3953 million yuan for the first three quarters of 2025, showing improvement compared to previous years, but the stock price continued to decline [8]. Group 3: Fundraising and Project Performance - The company raised approximately 1.296 billion yuan during its IPO, but many fundraising projects have not met expected returns or timelines [1][2]. - Specific projects, such as the Beijing and Chongqing new hospital projects, have incurred significant losses, with cumulative losses of 90.8468 million yuan and 69.5107 million yuan, respectively [3][6]. - The company has announced delays in project timelines, extending the expected operational status for several projects to 2026 and 2027 [5][6]. Group 4: Shareholder Actions - The fourth largest shareholder, Advanced Manufacturing Industry Investment Fund, plans to reduce its stake by up to 310,610 shares, representing 1.97% of the total shares [9][10]. - Previous reductions by the same fund have already occurred, indicating a trend of shareholder exits amid declining stock performance [10][12].

Policy Developments - The State Administration for Market Regulation has approved the national standard for "Classification and Determination of Traditional Chinese Medicine Constitution," which will be implemented from April 1. This standard categorizes nine basic types of TCM constitution and aims to enhance health literacy and optimize health service models [2]. Medical Device Approvals - Opcon Vision's application for the registration of "soft hydrophilic contact lenses" has been accepted by the National Medical Products Administration, currently in the acceptance phase [4]. - Livzon Pharmaceutical announced that its clinical trial application for injectable brexpiprazole microspheres for treating schizophrenia has been accepted by the National Medical Products Administration [5]. Capital Markets - AstraZeneca will acquire the remaining 50% equity of Westman Biotech's GPC3 armored CAR-T therapy in China, with a potential payment of up to $630 million, including upfront and milestone payments [7]. - Aote Biological's controlling shareholder has proposed a share buyback plan using funds from its IPO, with a total amount between RMB 100 million and RMB 200 million [8]. Industry Developments - Alibaba Health has launched its self-developed AI medical model "Hydrogen Ion," which is now in practical application, targeting clinical and research fields. This move complements Alibaba's existing health service strategies [10][11]. - Jiangzhong Pharmaceutical has changed its name to "China Resources Jiangzhong Pharmaceutical Co., Ltd." and will also change its stock abbreviation to "China Resources Jiangzhong," while keeping the stock code unchanged [12]. Shareholder Actions - Liaoning He Eye Hospital Group has received a notice from a major shareholder planning to reduce its stake by up to 3,106,074 shares, representing 1.97% of the total share capital, between February 7 and May 6, 2026 [14].

Group 1: Important Market News - The People's Bank of China and the National Financial Regulatory Administration announced that the minimum down payment ratio for commercial housing loans is adjusted to no less than 30% [1] Group 2: Industry Insights - Domestic commercial aerospace companies are advancing their IPO processes, with China Aerospace Science and Technology Corporation's subsidiary, Zhongke Yuhang, changing its listing guidance status to acceptance. The company aims to become the first commercial aerospace stock in China [2] - The satellite communication industry is projected to reach a market size of 200 to 400 billion yuan by 2030, with an annual compound growth rate of 10% to 28%. This sector is transitioning from "concept validation" to "scale application," driven by technological maturity and cost reduction [2] - Major internet companies in China, including Alibaba, ByteDance, and Tencent, are intensifying competition in AI application products. Alibaba's newly launched Qianwen APP aims to serve as a personal AI assistant, integrating various services within its ecosystem [3][4] - Alibaba's Qianwen APP achieved over 10 million downloads within seven days of its launch, making it the fastest-growing AI application, directly competing with ByteDance's Doubao [4] - The brain-computer interface sector is gaining traction, with significant investments and advancements. A startup, Merge Labs, raised $252 million in seed funding, indicating strong interest in this technology [5][6] - The global market for brain-computer interface medical applications is expected to reach $40 billion by 2030 and $145 billion by 2040, highlighting its potential in treating neurological disorders [6] Group 3: Company Updates - Rongbai Technology is under investigation by the China Securities Regulatory Commission for misleading statements regarding a major contract [7] - San Da Membrane announced a plan to reduce its shareholding by up to 996,040 shares, representing no more than 3% of its total share capital [7] - He Shi Eye Hospital's shareholder plans to reduce its stake by up to 310,610 shares, accounting for 1.97% of the total share capital [7] - Jinke Environment reported a planned reduction of up to 102,520 shares by a significant shareholder, representing 0.83% of the total share capital [7] - Wei Si Medical announced a plan to reduce its shareholding by up to 287,310 shares, which is 3% of its total share capital [8] - Sifangda's controlling shareholder plans to reduce its stake by up to 483,150 shares, while other executives also plan to sell portions of their shares [8] - Chuhuan Technology reported a planned reduction of up to 239,560 shares by its significant shareholders [8]

Group 1 - New stock subscriptions: Agricultural University Technology subscription code 920159, issue price 25 yuan/share, subscription limit 720,000 shares. Zhenstone Co. subscription code 780112, issue price 11.18 yuan/share, subscription limit 54,500 shares [6] - The China Securities Regulatory Commission (CSRC) held a system work meeting on January 15, 2026, emphasizing the need to maintain market stability and enhance monitoring and regulation to prevent market volatility [7] - The CSRC is investigating Rongbai Technology for misleading statements regarding a major contract, which the company estimated at a total of 120 billion yuan with CATL [9] Group 2 - Minexplosion Optoelectronics plans to acquire Xiamen Zhizhi Precision and Jiangxi Maida, both focusing on core consumables in PCB manufacturing [10] - Yanjing Co. intends to purchase 98.54% equity of Yongqiang Technology, expanding its business into high-end electronic interconnection materials for integrated circuits [11] - Qizhong Technology plans to invest 50 million yuan in a stake in He Xin Integrated, a company in the advanced packaging and testing field [12] Group 3 - Tianyuan Intelligent's actual controller and chairman, Wu Yizhong, has been detained [14] - Tian Tie Technology's actual controller, Xu Jiding, has had his compulsory measures changed to bail pending trial [15] - Guolian Minsheng expects a net profit increase of approximately 406% year-on-year for 2025 [16] Group 4 - Oke Yi anticipates a net profit increase of 67.53% to 91.96% year-on-year for 2025 [17] - I Love Home expects a net profit increase of 40.78% to 56.42% year-on-year for 2025 [17] - Longi Green Energy expects a net profit loss of 6 billion to 6.5 billion yuan for 2025 [17]